Toggle Offcanvas
...
 
Mepolizumab Tenders

Mepolizumab Tenders

View Mepolizumab tenders, RFPs and contracts. Bid on readily available Mepolizumab tenders with the best and most comprehensive tendering platform, since 2002.

Bidding for Mepolizumab tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Mepolizumab.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Mepolizumab market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Mepolizumab tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

60 Live Notices for Mepolizumab Tenders

Showing 1 to 20

Error 500 (Server Error)!!1500.That’S An Error.There Was An Error. Please Try Again Later.That’S All We Know.
country Spain
posting date07 Feb 2025
deadline11 Jul 2025
Environmentally Friendly Supply Of Medicines For Human Use Whose Active Ingredients Are Belimumab, Mepolizumab And Niraparib, Destined For Centers Within The Scope Of The Valencian Public Health System
country Spain
posting date06 Feb 2025
deadline21 Feb 2025
Mepolizumab 100Mg/Ml, Injectable Solution, In Filled Syringe Or Application Pen - .60 Units
country Brazil
posting date04 Feb 2025
deadline19 Feb 2025
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026

Share Share this page